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ABSTRACT 
 
The purpose of this IQP is to show the current state and issues of stem cell 
research, and its impact on society.  Its purpose is to persuade its readers to have a more 
open mind towards stem cell research, and to at least support some types of stem cell 
research that do not involve destruction of an embryo.  It will explore the types and 
sources of stem cells, the uses of stem cells, and the ethics and laws pertaining to stem 
cell research. 
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EXECUTIVE SUMMARY 
 
 Stem cells are long-lived cells in the body that have the ability to differentiate into 
specialized cells to create new tissues and are capable of self regeneration.   A common 
misperception is that not all stem cells are equal, there are many different types.  Some 
stem cells, such as embryonic stem cells have the potential to form many diverse tissues, 
while others that are more specialized can only form a few or even just one type of cell.  
Stem cells can be classified  by potential or source.  When classifying by potential 
(greatest potential first) the categories are:  totipotent, pluripotent, mulitpotent, unipotent.  
Unlike any other human cell, a totipotent cell has the natural ability to form every cell in 
the human body, including the extra embryonic cells.  Pluripotent stem cells are very 
similar to totipotent stem cells but can not make extra embryonic cells, ES cells are 
pleuripotent.  Multipotent stem cells are stem cells that can produce a limited subset of 
cells, examples include neural stem cells and hematopoietic stem cells.  Unipotent stem 
cells are similar to normal cells in the body, but unlike a regular cell, they are considered 
stem cells because they are self replicating.  An example of unipotent stem cell is 
epithelial stem cells. 
 The second way to classify stem cells is by the type of tissue from which they are 
isolated.  The two types are: adult stem cells and embryonic stem (ES) cells.  ES cells are 
not specialized and have a greater natural potential.  Adult stem cells are stem cells that 
are more specialized and are partially differentiated.   
 Considerable misinformation exists on exactly what has been achieved with stem 
cells to date.  Since the fifties when bone marrow transplants with hematopoietic stem 
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cells were originally conducted, stem cell therapies have successfully evolved from one 
method of treating leukemia, into a more modern and technologically advanced approach 
to medicine in which stem cells and advanced harvesting techniques are used to combat 
all types serious medical conditions such as heart disease, diabetes, Multiple Sclerosis, 
and even in the repair of spinal cord injuries.  Hematopoietic stem cells can be used to 
treat diseases of the blood such as leukemia, through treatments such as bone marrow 
transplants.  Hematopoietic stem cells have also been used to treat immune system 
disorders, such as Crohn’s disease, Behcet disease, and Krabbe disease.  Pancreatic stem 
cells can be used to grow islet cells to combat diabetes.  Stem cells, from the brain or 
nasal cavity of mice, have been used to trigger the regrowth of myelin in mice with 
multiple sclerosis.  Adult stem cells (neural) have also been used to treat Parkinson’s 
disease, through transplantation.  An area of ongoing research is the treatment of spinal 
cord injuries with neural stem cells.  There is also much research into the treatment of 
cancer and other diseases with stem cells. 
 As with most new technologies, stem cells are highly controversial.  The moral 
dilemmas presented by stem cell research are as diverse as the research.  These concerns 
take the form of both moral and religious objections.  Catholics are against all ES and EG 
research, while Muslims and Jews feel that these areas of interest can be explored in a 
morally upright fashion, so long as the research saves human lives.  The main issues with 
ES and EG research are: when does life begin, is the greater good a valid argument, and 
how does ES and EG research affect the donors.  Those that believe life begins at 
conception tend to see ES research as morally wrong, while those who believe otherwise 
often can justify it for the “common good”.  The issue of parthenotes, embryos without 
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the ability to grow into a human, provides a possible alternative source for ES cells, but 
also has its opponents. 
 Laws are currently in place in most countries to regulate stem cell use.  Whether 
the laws are strict or lenient depends on the country.  Some countries like England and 
Sweden have liberal laws that allow most stem cell research.  Other countries allow 
research as long as the ES cells are taken from a line derived from embryos from fertility 
clinics.  The most strick countries do not allow any ES cell research. 
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PROJECT OBJECTIVES 
 
The purpose of this project was to examine the highly controversial topic of stem 
cells, to discuss its impact on society, and to address many of the common 
misconceptions about stem cell research.  This report is intended to serve as an 
introduction to the types of stem cells and their various sources, stem cell applications, 
the ethics concerning their research and use, as well as the laws that have been enacted to 
regulate and govern further research and developments.  These issues were researched 
through the investigation of articles pertaining to both ongoing and previously conducted 
stem cell studies that were found in journals, newspapers, magazines, and on the internet.       
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CHAPTER-1:  STEM CELL INTRODUCTION:  
TYPES AND SOURCES 
 
 Stem cells are long-lived cells in the body that have the ability to differentiate into 
a specialized cell to create new tissues.  Because of this tissue regenerative capacity, stem 
cells are of current medical interest.  However, obtaining one type of stem cell, 
embryonic stem (ES) cells, destroys a living embryo, so many individuals are against 
their use.  But ES cells are only one type of stem cell.  The purpose of this chapter is to 
document the various kinds of stem cells, describing their potential and their sources. 
 
Tests for Stem Cells 
 It is not easy to know when you have isolated a stem cell for use, but certain tests 
are commonly performed.  The first test is to culture the cells for several months and 
make sure they remain undifferentiated.  A cell that remains undifferentiated is a cell that 
has the same characteristics as its parent cell.  Differentiated cells tend to be more 
specialized than their parent cell.  This test assures that they have the potential for long 
term, self renewal.  Another test is to identify certain surface markers that are only 
present on undifferentiated cells.  For example, for Oct-4 is a transcription factor protein 
that turns genes on and off.  This protein is present in many kinds of stem cells, and may 
help them differentiate  (Stem Cell Basics- 2005).  If scientists learn to control the action 
of this protein, and other proteins like it, someday it may be possible to grow replacement 
body parts, such as a kidney or heart.    
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 Another test of stem cells is to make sure that they can differentiate into multiple 
types of cells.  For example, for hematopoietic stem cells (HSCs) that form all the 
cellular components of blood, one such test is to inject them into a mouse that has been 
irradiated to kill off its own blood cells.  If the mouse recovers and replenishes its blood 
supply, the injected HSCs are assumed to be stem cells.  This test shows plasticity, the 
ability to form several types of cells, and self renewal. 
 
Stem Cell Classification 
 Stem cells can be classified in several ways.  The first way is by potential.  Some 
stem cells have the potential to form many diverse cells, while others only can form a few 
or even just one type of cell.  The divisions when classifying by potential (greatest 
potential first) are:  totipotent, pluripotent, mulitpotent, unipotent.  Each of these will be 
discussed in detail below.  While the potential of each type is different, they all have 
potential medical applications.  Recent research has shown that stem cell potential may 
partially be a result of environment.  Cells from the brain, that normally produce neural 
cells, have been shown to grow blood cells when transplanted into bone marrow 
(Generalized Potential of Adult Neural Stem Cells- 2000).  Thus, classifying by potential 
is done based on the cell’s natural tendencies.    
 The second way to classify stem cells is by the type of tissue from which they are 
isolated.  The two types are: adult stem cells and embryonic stem (ES) cells.  ES cells are 
stem cells isolated from embryonic stages of development.  These cells are not 
specialized and have a greater natural potential.  Adult stem cells are stem cells that are 
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more specialized and are partially differentiated.  These cells are found in humans, even 
before birth.  There are more types of adult stem cells than ES cells. 
 
The basis for the formation of all cells in the human body is totipotent stem cells.  
These cells are represented by the single cell zygote, which is formed when a sperm cell 
fertilizes an egg.  Unlike any other human cell, a totipotent stem cell has the natural 
potential to form every cell in the human body including the extra embryonic cells.  The 
extraembryonic cells include the trophoblast, amniotic sac, and umbilical cord.  Without 
the trophoblast, the embryo cannot be implanted to continue its development.  Every 
human starts as a single totipotent stem cell.  This single cell divides into more totipotent 
stem cells (this point is debatable, some scientists believe cells through the 4-8 cell stage 
are totipotent), which in turn differentiate into more specialized cells.   A single totipotent 
stem cell, for this reason, is capable of forming an entire human being.  This is one aspect 
of stem cell research that sets off moral triggers.  People feel that doing scientific 
research with what could potentially develop into a human being, is unethical.  Totipotent 
cells are self replicating, such that an entire line of stem cells can be created from just a 
few.  By not needing to constantly have a fresh source of cells, the moral issues with the 
harvesting the cells are reduced in the eyes of some. 
Pluripotent stem cells are very similar to totipotent stem cells.  After around 4 
days post-fertilization, the embryo exists as a blastocyst, which is a hollow shell of cells 
containing an inner cell mass.  The inner cell mass is of much interest to researchers, as it 
consists of pluripotent ES cells.  The only cells that pluripotent ES cells cannot form are 
the extra-embryonic cells.  Other than these cells, needed for implantation, pluripotent 
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cells can form any cell in the human body.  This subtle but important difference is what 
separates the pluripotent from totipotent.  Like totipotent and all other stem cells, 
pluripotent stem cells are self replicating and are capable of producing a line of ES cells.  
Because these cells cannot naturally form the cells needed for implantation alone, these 
cells do not have the ability to form a human being.  This is an important distinction, as 
doing research with these cells is not doing research with a human life.  However, the 
problem is that to harvest the pluripotent ES cells, the blastocysts must be destroyed 
(Figure-1).  As of now, the technology does not exist to allow the harvesting of part of 
the inner cell mass, while leaving the rest of the embryo intact.  If researchers were able 
to remove only part of the inner cell mass and not harm the blastocyst, the remaining 
cells would theoretically be able to still be implanted and grow to term.  Such an advance 
would remove some of the moral issue with ES stem cell research, especially the 
reservations to creating new ES cell lines. 
 
 
 
 
 
 
Figure-1:  Isolation of ES cells from a Blastocyst 
(Pinceton.edu Blastocyst Tutorial) 
 
Multipotent stem cells are stem cells that can produce a limited subset of cells.  
Multipotent stem cells are adult stem cells.  While self replicating, and able to produce a 
variety of cells, mulitpotent cells naturally only produce cells of a similar type.  For 
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example, hematopoietic stem cells (HSCs) can produce red and white blood cells, but do 
not normally produce muscle or nerve cells.  HSCs can produce a variety of blood and 
immune system cells, including red and white blood cells, lymphocytes, natural killer 
cells, and platelets, and reside in bone marrow (Green- 2001) (Figure-2).  HSCs are also 
called ‘blood stem cells’.  These cells have shown great potential and play a large role in 
bone marrow transplants.  Hematopoietic stem cells could be used to produce a reliable, 
sufficient blood supply. 
 
 
 
 
 
 
 
 
 
Figure-2:  Differentiation of Bone Marrow Hematopoietic Stem Cells 
(Stem Cell Basics, 2005). 
 
 
Another type of mulitpotent stem cell is neural stem cells.  These cells can form 
neurons, astrocytes, and oligodendrocytes  (Joshi and Behari, 2003).  Neural stem cells 
exist in adults in the liver, pancreas, and brain.  Mesenchymal stem cells are also 
multipotent, and can produce new bone cartilage and connective tissue.   
 Unipotent stem cells are also adult stem cells.  They are similar to normal cells in 
the body, but unlike a regular cell, they are considered stem cells because they are self 
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replicating.  They can self replicate but unlike any other type of stem cell, they cannot 
form another type of cell.  An example of unipotent stem cells is skin cells.  These 
unipotent stem cells can produce more skin cells, but cannot differentiate and create other 
tissue. Though useful in a specific application, such as new skin cells for burn patients, 
the unipotent stem cell does not have the widespread potential that other stem cells have.   
Unipotent stem cells are also found in the brain.  These cells have great medical potential, 
especially in cases of brain damage, where new neurons could be grown to replace 
damaged neurons.  These stem cells have only recently been found in adults.  The earliest 
indication that neuronal stem cells exist came in 1992 and 1993 (Reynolds and Weiss, 
1992; Lois and Alvarez-Buylla, 1993; Morshead et al, 1993).  In 1998, Eriksson, showed 
that adult neural cells are generated in the hippocampus.  These cells then migrate to their 
final positions in the brain.   
 As mentioned above, when classifying stem cells by source there are adult stem 
cells and embryonic stem cells (ES).  Although each is a valid source of useable stem 
cells, their usefulness varies greatly.  ES cells are the most useful as they are the least 
differentiated.  On the other hand, adult stem cells are more specialized, and therefore 
have less potential.  Adult stem cells have many different types and can be harvested in a 
nonfatal manner.  The ability to harvest adult stem cells, without the destruction of a 
potential human life, is one reason why adult stem cell research should be strongly 
supported. Though these cells are more specialized than ES cells, they still are quite 
useful and are being found to have much greater potential than once was thought.  
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Umbilical Cord Stem Cells 
 Umbilical cords are a great source of multipotent adult stem cells.   Umbilical 
cord stem cells should not be considered a moral threat.  They are isolated from a 
recently born baby’s umbilical cord blood.  These cells are harvested without harming the 
baby, and are cells that would normally be discarded and die.  A recent trend is to save 
and freeze these cells as to provide a source of stem cells in case the child should need 
them later in life.  The umbilical blood cells are used in marrow replacement treatments.  
These cells are useful not just for the child, but can also be used in marrow replacement 
for related and unrelated patients.  The umbilical cord contains large amounts of 
hematopoietic stem cells, much larger concentrations than the marrow of an adult 
(Viacell, 2006).  The umbilical cord also contains high concentrations of high level 
progenitor cells.  Progenitor cells are parent cells that produce a line of cells that are more 
specialized than the parent cells.  Marrow replacement is commonly used to treat 
leukemia, certain other cancers, and some blood disorders.  The marrow is typically taken 
from a healthy related marrow donor.  The injected stem cells colonize the patient’s 
marrow, and differentiate to form new blood components.  Patients with marrow 
replacement that uses umbilical cord blood cells, rather than adult marrow, have a higher 
recovery rate, due to the higher concentrations of progenitor cells and hematopoietic stem 
cells.   
 The umbilical cord blood also has a greater expansion potential than the adult 
marrow, due to the presence of less specialized stem cells.  Transplantation from 
umbilical cord blood is also less likely to result in tissue rejection.  This is thought to be 
due to the unspecialized stem cells in umbilical cord blood.  They have not yet developed 
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all of the surface markers that are present on most adult cells.  The lack of these markers 
makes the patient’s immune system more likely to ignore the graft.  The umbilical cord 
blood also has less immune cells than adult blood.  This helps minimize the rare cases of 
graft verse host disease, where the immune system cells in the graft attack the host’s 
body.  The advantages of umbilical cord stem cells over marrow cells clearly illustrate 
some of the reasons that scientists prefer to work with less specialized stem cells, such as 
ES cells.  Some umbilical cord stem cells have the same surface markers as ES cells, 
giving hope that someday umbilical cord stem cells could be used in place of ES cells in 
research.  Umbilical cord stem cells have been convinced to create liver and pancreatic 
cells in vitro.  Though these cells have not been used yet to treat non-blood disorders, 
there is hope that someday they could be used to treat diseases such as diabetes.  
Mesenchymal stem cells are also found, in low concentrations, in umbilical cord blood 
and, in larger concentrations in the Wharton’s jelly in the cord. 
 
Bone Marrow Stem Cells 
 
Bone marrow contains several types of adult stem cells.  The main type of stem 
cell found in bone marrow is hematopoietic stem cells.  These stem cells also are found in 
the peripheral blood but in much lower concentrations.  In the blood, HSC are found at a 
rate of about 1 in 100,000 cells, while in marrow the rate is 1 in 10,000 (Stem Cell 
Basics- 2005).  The higher concentration of stem cells allows for a marrow transplant to 
be more effective than a blood transfusion in treating blood disorders or aiding the 
recovery of the hematopoietic system.   
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These hematopoietic stem cells are hard to identify in culture because they act and 
appear like many other blood and marrow cells.  For example, some HSC have the same 
appearance as ordinary white blood cells.  The only way of telling these cells apart is the 
HSC’s ability to self replicate and to differentiate into other cells.  This can be a time 
consuming and frustrating test, as the cells cannot be isolated on an individual level and 
therefore it is impossible to be certain that all of the cultured cells are HSCs.    
Another type of stem cell found in bone marrow is the mesenchymal stem cell 
(MSC).  These cells are also known as marrow stromal cells.  MSC are commonly 
isolated from the marrow aspirates taken from the iliac crest.  MSC can form osteoblasts, 
chondrocytes, myocytes, adipocytes, and neuronal cells.   Osteoblast cells secrete osteoid, 
a substance with high concentrations of collagen, which mineralizes and forms bone.  
These cells play an important role in maintaining bone strength.  Chondrocytes are the 
cells that build and maintain cartilage.  Myoctes are commonly referred to as muscle 
fiber.  Cardiac (smooth) muscle cannot repair after an injury, unlike skeletal muscle.  
Because of this limitation, MSC hold vast medical promise for the treatment of cardiac 
problems.  Scientists hope to use MSC to grow new cardiac cells, to repair a damaged 
heart.   Adipocytes are the main adipose tissue (fat) cells.  
 
Brain and Spinal Cord Stem Cells 
The brain and spinal cord are another location containing stem cells.  They 
contain Neural Stem Cells (NSC) (Figure-3) that differentiate into cells such as neurons, 
astrocytes, and oligodendrocytes.   
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Figure-3:  Neural Stem Cells. 
Reneuron reneuron.com. 
 
 
Research has shown that NSC exposed to retinoic acid differentiate into neurons 
(Huettner, 2006).  Astrocytes are glial cells that provide physical support, nourishment, 
and maintain the environment for neurons.  Oligodendrocytes perform a similar role for 
axons- they nourish and provide support for the axons.  Oligodendrocytes also produce 
the myelin sheath that protects axons.  The ability to produce oligodendrocytes makes 
NSC useful in multiple sclerosis and leukodystrophy research, diseases that attack the 
myelin sheaths.  NSC have been proven to form hematopoietic cells when grafted into the 
bone marrow of mice.  This plasticity, outside of what has been observed in nature, 
suggests that part of the limitation on stem cell plasticity comes from the stem cell’s 
environment (Generalized Potential of Adult Neural Stem Cells- 2000).   Recently, two 
more types of stem cells have been found in the brain.  These are ependymal cells and 
subventricular zone astrocytes.  These cells were found to form neurospheres, just like 
NSC. 
Parthenotes 
One exciting new development in ES research is parthenotes.  In nature, certain 
species, such as turkeys, aphids, and especially insects like bees and ants, are capable of 
reproducing in an unusual manner.  The female is able to produce offspring without the 
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male.  Their eggs divide on their own, and grow into adulthood.  These offspring are 
referred to as parthenotes.  Scientists are conducting research into achieving this with 
mammalian eggs.  The eggs are chemically treated to replicate the arrival of sperm.  The 
eggs then divide and form blastocyst embryos, but these embryos can not develop past an 
early fetal stage.  Initial human parthenotes were found to be peculiar, as they did not 
contain stem cells (at the 100 cell developmental level) (Cibelli et al., 2001).  Research 
has since shown that it is possible to derive ES cell lines from monkey parthenotes 
(Cibelli et al., 2002).  Very recently, claims exist for the development of ES cell lines 
from human parthenotes (Marchant, 2006).  These impotent synthetic embryos may 
provide moral relief for ES research.  Because they cannot result in an adult, some 
scientists consider parthenotes as morrally separated from traditional embryos.  
Parthenotes have great medical promise as a source of genetically identical tissue 
transplants that the body would not reject.   
Male parthenotes have also been shown to be feasible.  The genetic coding is 
removed from an egg and two sperm, from the same donor, are added.  The egg is then 
chemically treated to divide.  This has the potential to be useful for male patients, who 
might need replacement tissue. 
 
Embryonic Germ (EG) Cells 
EG cells are taken from the tissue of aborted fetuses.  The cells are set aside by 
the body for future reproduction.  The fetuses are typically aborted around 7 to 9 weeks 
after conception, and thus are a highly controversial source of stem cells.  These EG cells 
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are isolated from human fetal gonads (Figure-4).  The germ cells are pluripotent and can 
differentiate into three germ lines: ectoderm, mesoderm, and endoderm.  Because these 
cells have similar potential to the ES cells, some researchers feel these are an alternative 
to ES cells.  These cells have great application potential, as they are seem to be less likely 
to form tumors when transplanted, as compared to ES cells.  Because the body only 
begins with 50 of these cells, they are difficult to isolate. 
 
Figure-4:  Derivation of Embryonic Germ (EG) Cells 
(Fetal Tissue Diagram, 2006) 
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CHAPTER-2:  STEM CELL APPLICATIONS 
 
 While the debate about embryonic stem cell harvesting and use by doctors and 
scientists remains at the forefront of the stem cell debate being conducted by politicians 
and world leaders, doctors and other members of the medical community have been 
developing new ways for stem cells to be utilized in the treatment of a variety of medical 
conditions and diseases for many years.  While the technology and applications of stem 
cell therapies may be constantly advancing, the idea of using stem cells as a treatment 
method is far from a novel idea, as there have already been more than seventy medical 
conditions successfully treated by the use of stem cells in documented studies (Earll, 
2005).  Many people who are ethically against the use of “stem cells” do not realize that 
different types of stem cells have been used by doctors to treat of many different medical 
ailments for more than fifty years.  Another common misconception believed by the 
public is that all stem cell research and therapies used by doctors rely upon the 
controversial embryonic stem cells (ES).  The stem cells primarily used in these early 
therapies are not ES cells whose harvesting require the termination of a living organism, 
but instead are adult stem cells that can be non-fatally harvested from tissues such as 
umbilical cords, pancreases, eyes, skin, and brains (Earll, 2005).  Since the fifties when 
bone marrow transplants with hematopoietic stem cells were originally conducted, stem 
cell therapies have successfully evolved from one method of treating leukemia into a 
more modern and technologically advanced approach to medicine in which stem cells and 
advanced harvesting techniques are used to combat all types serious medical conditions 
such as heart disease, diabetes, Multiple Sclerosis, and even in the repair of spinal cord 
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injuries (Earll, 2005).   Stem cell therapy aims to replace the “master cells” that 
differentiate into the cells that have become damaged or destroyed by diseases or trauma 
with therapeutic cells that trigger the body into naturally repairing the damage and 
hopefully reversing the effects of the condition that the patient suffers from (Escolar et 
al., 2005).  Due to a great deal of misinformation on the web concerning what has 
currently been achieved with stem cells versus what is hype, the purpose of this chapter is 
to document some of the real studies that have been done with stem cells. 
 
Adult Stem Cell Applications 
 
Hematopoietic Stem Cells 
One of the earliest and most commonly used stem cell applications over the past 
half century was the transplantation of healthy bone marrow into a patient who was 
suffering from a disease that destroys the body’s immune system such as leukemia.  
Leukemia and other diseases like it result in an immunodeficiency disorder caused by 
improperly functioning bone marrow.  Leukemia is actually a type of cancer that is 
commonly associated with children and young adults that destroys bone marrow, which 
is the tissue that contains hematopoietic stem cells (HSCs) which are responsible for 
making all the cellular components of blood such as white blood cells, red blood cells, 
and platelets.  Leukemia results in the body having a high level of immature white blood 
cells, which in turn can lead to the likelihood of the patient becoming increasingly 
susceptible to infections and weakness as the illness progresses.  There are two common 
leukemia treatment procedures used by doctors.  In the first treatment option, doctors 
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harvest healthy bone marrow from a location in the same patient where the marrow is 
deemed ‘healthy’ and transplant it into the area affected by the cancer, in what is called 
an autograft procedure.  Another option the doctors can choose is to remove healthy bone 
marrow from a separate matching donor patient which can then be transplanted into the 
sick patient in what is termed an allograft procedure.   Using an allograft is advantageous 
if a good matching donor is available for the transplant because in most cases the patient 
himself has a severely weakened immune system, and does not have enough healthy bone 
marrow that can be harvested and transplanted.  The transplanted bone marrow contains 
the hematopoietic stem cells that recolonize the patient’s bone marrow, and differentiate 
into the necessary cell types that allow the body to naturally produce healthy bone 
marrow and blood, hopefully producing healthy mature white blood cells, and ultimately 
increasing the ability of the patient’s immune system to function normally.   
The first successful bone marrow transplant that resulted in long term survival of 
a patient suffering from leukemia was performed by Dr. Donnall Thomas in 1956 
(Piccolo, 2006).  Dr. Thomas removed bone marrow from a healthy twin sibling which 
was then transplanted into the sick patient.  This procedure caused the leukemia 
symptoms to recede over time, eventually putting the cancer into remission.  The next 
advance in leukemia treatment came when doctors were able to successfully match and 
transplant bone marrow from a donor which was not related to the sick patient.  When an 
unrelated donor must be used, a healthy matching source is found, and the bone marrow 
is removed from the donor’s hip in a minimally invasive procedure.  The first successful 
bone marrow transplant involving the use of marrow from an unrelated donor was 
conducted on a five year old boy in 1973 at the Sloan-Kettering Cancer Center in New 
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York.   A matching donor was found in Denmark, and the child required seven different 
marrow transplants to allow his body’s immune system to function normally (Piccolo, 
2006).   
 
Treatment of Diabetes with Adult Pancreatic Stem Cells 
Diabetes is a serious condition caused by the improper function of the pancreas.  
In a healthy human, the pancreas produces insulin, which is a chemical needed by cells to 
use the glucose in the body that comes from food, the liver, and muscles.  A Type-I 
diabetic is someone whose pancreas does not properly function, meaning that little or no 
insulin is produced by their pancreas.  There are two types of diabetes, Type I and Type 
II.  Type I diabetes is also known as “Juvenile Diabetes” and is a condition where the 
pancreas does not produce any insulin at all, while Type II diabetes results in the 
pancreas producing insufficient insulin levels later in life (or the body quits being 
sensitive to the insulin that is made), hence its other name, “Adult Onset Diabetes.”  Over 
time, the excess glucose levels in the blood can result in both temporary and permanent 
health problems ranging from a minor problem like fatigue, to a major one like blindness 
or even death  (What is Diabetes?, 2005).  Diabetes stem cell therapy requires the 
harvesting and implementation of pancreatic stem cells which are used to grow new islet 
cells which are destroyed by diabetes.  This type of therapy has been shown to have the 
potential to decrease the need for pancreas (or kidney following pancreatic failure) 
transplantation in patients suffering from diabetes, as it helps the pancreas to function 
properly and naturally supply the body with insulin.  One study shows that one year after 
islet cell transplantation, many diabetics’ pancreases are functioning at normal levels, 
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meaning the patient no longer requires the frequent insulin injections (Hughes, 2005).  
Researchers at Harvard recently conducted a trial on mice where mice suffering from 
Juvenile Diabetes were injected with adult stem cells.  This therapy resulted in the 
complete disappearance of all symptoms of diabetes in the mice, and is awaiting clinical 
trials in human patients (Kodama et al., 2003).  Another study conducted first with ES 
cells from mice, then with human ES cells, has shown that embryonic stem cells could 
also be used in therapies to treat diabetes.  The ES cells differentiated into islet cells that 
produce insulin. This study is discussed in more detail below in the subsection on ES 
cells.   However as this treatment method would require the use of the ethically 
controversial ES cells, it is not a viable treatment method in human patients at the present 
time (Assady et al., 2005).  Future use of stem cells to efficiently treat diabetes without 
requiring an organ transplant or long term dialysis use would be ideal, as the supply of 
matching, healthy organs, and the high costs and risks associated with dialysis are severe 
problems for doctors, insurance companies, and patients to overcome (Earll, 2005). 
 
Treatment of Multiple Sclerosis with Adult Stem Cells 
Multiple Sclerosis (MS) is a disease that affects the Central Nervous System 
(CNS) which can create a variety of degenerative health problems for people suffering 
from it.  Normal, healthy people have a layer of myelin that acts as a sheath and 
surrounds the nerves in the body.  This myelin tissue sheath protects the nerves and also 
helps the body conduct nerve impulses which control all of the body’s functions.  MS 
patients experience a gradual breakdown of the myelin layer surrounding their nerves, 
resulting in the formation of sclerosis, also known as scar tissue regions, around the 
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nerves.  The scar tissue prevents natural regeneration of the myelin sheath, ultimately 
leaving the nerves unprotected and incapable of proper nerve impulse conduction.  MS 
eventually results in nerve damage that can cause painful long term health problems such 
as bladder and bowel dysfunction, feelings of vertigo, and problems walking, and even 
seizures (About MS, 2005).   
Over the years, a variety of therapies have been used to combat MS, ranging from 
drug treatments to physical therapy regimens.  Now many doctors are conducting studies 
on the use of stem cells to help treat MS.  Adult stem cells are harvested from the brain or 
nasal cavity of mice, and implanted in the areas afflicted by sclerosis in a mouse MS 
model to trigger natural myelin growth, and help the body repair the lesions formed by 
the disease.  It has been shown in some studies to successfully stabilize or even reverse 
many of the symptoms (Earll, 2005).   
 
Treatment of Parkinson’s disease Using Adult Neural Stem Cells 
Parkinson’s disease is another condition that like MS affects the central nervous 
system.  It is caused by the destruction of dopamine producing brain cells.  Dopamine is a 
chemical needed by the body for normal motor skills and movement.  Parkinson’s is a 
degenerative disease that results in the gradual deterioration of patient’s bodily control, 
leading to symptoms such as uncontrolled muscle spasms and a decline in coordination.  
For years the primary method of treating Parkinson’s disease has been very long-term 
drug treatment programs, which have yielded mixed results.  The drugs have been 
successful in temporarily alleviating some of the symptoms and delaying the progress of 
the disease, but over extended periods of time the patients almost always experience a 
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worsening of symptoms as the disease overwhelms the drugs (Stem Cells, 2001).    
However in the late 1990’s neurologists began to experiment with the use of adult stem 
cells as a possible treatment for Parkinson’s disease.  One such trial was conducted on a 
man named Dennis Turner who had suffered from the effects of Parkinson’s for more 
than fourteen years.  Prescribed medication had become ineffective at controlling the 
symptoms, and by that stage Mr. Turner had almost completely lost control of the right 
side of his body, primarily experiencing extreme difficulty controlling the use of his 
arms.  Turner’s neurologist approved him for the stem cell trial, and neural stem cells 
were harvested from his brain and transplanted into the left side of his brain.  The cells 
were placed in the left half of his brain because the left lobe of the brain controls the 
function of the right side of the body where his paralysis was the worst (Levesque, 2002).  
The operation was a success, as Mr. Turner experienced almost complete remission of his 
condition, experiencing no new symptoms of Parkinson’s disease for more than four 
years, and he is considering undergoing another procedure to transplant more stem cells 
into the right half of his brain, hoping the further improve his condition.  Mr. Turner was 
able to return to a normal, active life after the procedure, something that would have been 
highly unlikely had he continued only on a drug therapy regimen (United States – Turner, 
2004).    
Other studies are also being conducted in the battle against Parkinson’s disease 
that do not require the harvesting and transplant of stem cells.  The patients are injected 
with a neurotrophic factor protein found in the body that induces the production of stem 
cells found in their own brain.  One year after the study, patients have experienced 
favorable results with their Parkinson’s symptoms, with more than sixty percent of the 
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patient’s who have had this protein injection showing increased mobility and reduction in 
symptoms of Parkinson’s (Gill, 2003).   
 
Use of Adult Hematopoietic Stem Cells to Treat Non-Blood Disorders 
Adult HSC transplants have also been successful in the clinical treatment of other 
autoimmune disorders such as lupus, Crohn’s disease, Behcet disease, and a degenerative 
genetic disorder that is similar to MS called Krabbe disease.  All of these disorders result 
in a breakdown of the afflicted person’s immune system, leading to the onset of health 
problems like pneumonia, intestinal and oral sores, skin lesions, blood deficiency, and 
abdominal discomfort.  The studies conducted show that many patients suffering from 
diseases resulting in insufficient immune system function that received hematopoietic 
stem cell transplants showed an improvement in their condition, or complete remission of 
their conditions.  Krabbe disease is a rare condition that arises in newborn children.  It is 
caused by a genetic abnormality that results in the body not producing an enzyme needed 
to form the myelin sheath needed to protect the nervous system.  If the disease is not 
caught soon after birth, the infant’s brain will not develop correctly and the newborn will 
begin to rapidly lose motor functions, and likely will die by the age of two.  Research 
teams in North Carolina have shown that if the newborn receives an immediate transplant 
of HSCs harvested from their own umbilical cord blood it can allow the infant’s body to 
naturally produce the myelin needed so that natural brain development can be restored 
(Stem Cell Research Foundation, 2005).   
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Treatment of Spinal Cord Injuries With Adult Neuronal Stem Cells 
Spinal cord injuries often result in paralysis that affects the patient’s use of their 
limbs, whether it is just the lower half of their body in the case of paraplegia, or both the 
legs and arms when the patient suffers quadriplegia.  These injuries typically occur when 
a person suffers a trauma which severely injures the spinal column, resulting in damage 
to the nervous system.  In years past, many doctors had offered a very grim prognosis to 
the people suffering these injuries as there were not any reliable therapies capable of 
reducing or completely reversing the paralysis.  Patients afflicted with paralysis usually 
faced a best case scenario where after many years of grueling physical therapy regimens 
they might regain some muscle and bladder control, and maybe some feeling in their 
limbs.   
However new studies that use adult neuronal stem cell transplants as part of a 
paralysis treatment program have had very positive results.  Neural stem cells are 
typically the stem cells that have been studied in connection with damaged nervous 
system therapies.  These neural stem cells are shown to be able to produce neurons, 
which are the cells mainly responsible for the transmission of most of the body’s 
electrical impulse.  Neural stem cells can be found in both fetal and adult brains, and can 
differentiate to form cells found both in the brain and spinal column (Stem Cells: 
Scientific Progress, 2001).  These stem cells are harvested from the patient and 
transplanted to the injured area.  Alternate sources for these stem cells used to induce 
regeneration of the nervous system include the nasal cavity and umbilical cord blood due 
to the cells from both sources contain neural stem cells, although these studies remain 
controversial.  Neuronal stem cells include cells that are used by the body to repair the 
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scar tissue that has formed along the spinal column and lead to myelin growth, as well as 
the formation of new nerves, ultimately allowing normal electrical impulses to be 
conducted by the nervous system (Hughes, 2005).  There are over sixty documented 
cases where patients have received these neuronal stem cell transplants and regained 
muscle control lost after the injury, and in some cases the patients are even able to walk 
again with the use of crutches or braces (Stem Cell Treatment, 2004).  One such case 
dealt with an 18 year old female from Colorado whose spinal cord was completely 
severed in an automobile accident, leaving her a quadriplegic.  Immediately after the 
accident it was determined by her doctors that not only she would never walk again, but it 
was unlikely that she would regain use of her arms either. However, with the help of 
friends and family she researched alternate treatments in hope of a miracle (United States 
– Peduzzi, 2004).  They found the Proneuron Biotechnologies Ltd. Company located in 
Israel that offered a stem cell and macrophage transplant therapy to help treat paralysis by 
allowing the body to naturally regenerate the spinal cord tissues that were destroyed by 
the trauma.  The procedure was a success, and has since returned muscle control and 
feeling to all four limbs (United States – Dominguez, 2004).  The success of these recent 
studies have given new hope to doctors and people suffering from paralysis worldwide, 
and are leading to more research into the use of stem cells as a means of combating 
paralysis.  
 
Treatment of Cardiovascular Disease with Adult Stem Cells 
Cardiovascular disease is the leading cause of death in the United States.  
Worldwide heart disease and heart trauma injuries are among the leading causes of death 
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in every country across the globe (Viacord, 2002).  There are over twenty million people 
worldwide who are at a high risk for suffering heart failure, and every year thousands of 
people are emitted to emergency rooms as a result of suffering severe heart trauma, so 
naturally the medical community is always searching for new methods for the prevention 
and treatment of the conditions that lead to heart disease and to save patients who suffer 
cardiac injuries (Aronow, 2005).  Many current conventional treatment methods used to 
combat heart conditions, such as drug therapies, the implantation of heart defibrillators 
and cardioverters, recommended exercise regimens, and dietary restrictions can be 
successful for short term results, but in the long term as the person ages it is common for 
the patient to experience another heart attack or cardiac episode.   
Doctors are now conducting studies on the use of HSCs or skeletal muscle stem 
cells to help restore normal heart function after patients suffer a heart attack, heart failure 
episode, or degenerative heart diseases.  HSCs or skeletal muscle stem cells are harvested 
from the patient’s body and transplanted into their arteries after they are stabilized.  It has 
been shown that this procedure can significantly increase the heart’s pumping ability, 
oxygen capacity, and cardiac tissue regeneration; all of which greatly increase the 
patient’s chances for long term survival after suffering a severe cardiac episode (Hughes, 
2005).   
A procedure conducted in 2003 illustrates the potential for stem cell therapies to 
help heal even the most severe cardiac problems.  A 16 year old Michigan boy suffered 
major cardiac trauma after being shot directly in the heart by a nail gun which lead to the 
boy eventually going into cardiac arrest.  His doctors initially determined that he would 
need to receive a heart transplant and undergo long term medication therapies to stabilize 
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his condition.  However, his doctors did offer an alternate treatment method and 
discussed with his family the use of an experimental stem cell procedure to help repair 
his heart.  This novel procedure had never been conducted on a human patient, and 
involved the transplantation of stem cells extracted from his body into his injured heart.  
Before the operation, doctors put the boy on a drug to stimulate the body into producing 
the stem cells needed for the procedure.  After a four day drug regimen doctors harvested 
the stem cells from the patient’s body, which were then transplanted into the arteries 
surrounding the heart using a heart catheter.  A team of doctors lead by Dr. William 
O’Neill completed the surgical stem cell transplant on February 21st, 2003, and within 
one week of the operation the teenager was able to be discharged as it was shown that the 
heart’s performance was steadily improving, with cardiac output increasing from twenty 
five percent before the procedure, to thirty five percent of normal output volumes after 
the transplant.  The stem cell transplant conducted by Dr. O’Neill’s team was truly the 
first of its kind and allowed the body to repair the tissues surrounding the heart that had 
been destroyed by the trauma on its own, instead of requiring multiple corrective 
surgeries.  The success of this operation will definitely lead to future research in the use 
of stem cells as a method of rapidly repairing damaged cardiac tissues without the use of 
highly invasive open heart surgery or heart transplant (Philipkoski, 2003).    
Studies are also being conducted on regenerating tissues other than those found in 
the nervous system, pancreas, and heart.  These studies have focused on tissues found in 
organs like the eyes, liver, and kidneys.  The cornea is a very delicate and crucial layer of 
tissue on the surface of the eye that acts as the eye’s primary means for focusing light.  If 
the cornea gets destroyed by disease or injury, it is likely the patient will suffer 
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significant loss of eyesight (Eye Bank Association of America, 2001).  Until recently 
there was little that could be done to help repair any damage to the cornea.  Corneal 
transplants, where healthy cornea tissue is harvested and transplanted onto the diseased or 
injured cornea, combined with limbal stem cell transplants are becoming a popular 
corneal blindness treatment method used by ophthalmologists.  Limbal stem cells are 
harvested from a healthy source and transplanted to the injured eye, in the hopes that they 
will differentiate into new corneal epithelial cells, improving the ability of the cornea to 
function normally (Schwab, 2000).  This combination treatment procedure has yielded 
very good results, with eyesight being successfully restored to patients that in some cases 
have been blind for more than forty years (Hughes, 2005).  Tissue regeneration through 
the use of stem cells as a treatment method for conditions causing failure in organs like 
the liver and kidneys are also being widely studied by the medical community.  Renal 
failure (kidney failure) is a very problematic condition, as it often leads to multiple organ 
failure if the condition is not quickly corrected.  Clinical trials have been conducted 
where patients suffering from kidney and multiple organ failure have received stem cells 
to help at least stabilize the tissues and increase the ability of these organs function until a 
complete organ transplant operation can be conducted.  
 
Treatment of Cancer Using Adult Stem Cells 
Cancer is a highly researched health problem, like heart disease, it is another one 
of the leading causes of death worldwide.  With many types of cancer, current treatment 
methods are not significantly effective in increasing the afflicted patient’s lifespan.  In the 
United States alone it was determined that over ten million people had died between the 
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years of 1950 and 1974 from various forms of cancer, and those numbers will rise 
dramatically over the next twenty five years as the population continues to grow 
exponentially, resulting in an increase of people at risk to develop terminal forms of 
cancer (Devesa et al., 1999).  Cancer is a condition where cell growth cannot be 
controlled by the body, resulting in the uncontrolled rapid production of cells.  The 
massive amounts of new cells produced by cancer can form into tumors that continue to 
grow and eventually overwhelm the body, and cause the death of cells needed for the 
body to function normally.  Cancer can be caused by the patient’s repeated exposure to 
outside factors like carcinogens, such as cigarette smoke or asbestos, that cause cell 
mutations, or cancer can also be caused genetically inherited traits that result in 
unnecessary cell differentiation (National Cancer Institute, 2005).  Many popular cancer 
treatments involve techniques such as chemotherapy and radiation therapy.  These 
methods have shown to be effective in at least slowing down the cancer or putting it into 
remission for some time, but both treatment options have negative side effects as 
radiation and chemotherapy do not exclusively target and kill the cancerous cells, but can 
cause cell death in healthy cells as well (Viacord, 2002).   
The medical community is now researching and developing the ability to use stem 
cells in the battle against many types of cancer.  It has been shown that the transplant of 
stem cells into cancerous regions of the body results in the formation of cells that target 
and attach themselves to the cancerous cells and can trigger cell death, eventually 
reducing the number of cancer cells and size of the tumor as the process repeats many 
times.  Aside from the formerly mentioned leukemia, stem cells have been successfully 
used in the treatment of cancers such as:  liposarcoma, Non-Hodgkins and Hodgkins 
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lymphoma, and neuroblastoma to name a few (Viacord, 2002).  After the positive results 
doctors have seen so far from these successful treatments, there is no doubt that as stem 
cell technology advances there will be more research into stem cell applications in the 
fight against all different types of cancer that effect millions of people annually.   
 
ES Cell Therapies 
 Embryonic stem (ES) cell therapies are among the most sought after medical 
advances as scientists conducting laboratory studies are just beginning to be able to 
harness a fraction of their power.  However, with as much support that the ES cell 
research movement has from the medical community and liberals around the world, there 
are just as many people who are concerned with the moral and ethical concerns that their 
use creates.  Because of these ethical concerns, ES cell studies have yet to be approved 
for human clinical studies, so as of now scientists have been relegated only to conducting 
ES cell tests in animal studies.  This is not abnormal though, as all new clinical 
procedures and treatments must first be shown to have positive results in pre-clinical 
studies conducted on animals before human trials are given approval.  ES cell animal 
studies have yielded positive results in tests conducted so far on the treatment of animals 
with diabetes or cardiac problems, giving researchers hope that soon they will be able to 
unleash ES cells as superior treatment methods for a variety of human medical 
conditions.  As scientists continue to make advances and conduct studies that are 
successful in showing the medical advantages to ES cell use it is likely that many people 
that oppose their use will see the benefits of ES cell therapies, resulting in the alleviation 
of some of the regulations which restrict researchers from openly pursuing human ES cell 
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applications.   
 As was briefly discussed earlier in this paper, an Israeli research team headed by 
Suheir Assady was successful in showing that it is possible to induce the differentiations 
of human ES cells into insulin islet cells.  This in vitro study was conducted on human ES 
cells that were allowed to differentiate. The resulting cell cultures were examined using 
an immunohistochemical staining technique that showed the successful production of 
insulin in the medium, meaning that there were islet cells produced (Assady et al., 2005).  
The results from this study are encouraging, but this technique’s application is still not 
ready for human in vivo studies.  
 However, the Assady study was based on an earlier in vivo study conducted by a 
team based in Spain on the treatment of diabetic mice using harvested rodent ES cells.  
Researchers from the Institute of Bioengineering at Miguel Hernandez University in 
Alicante, Spain were able to use ES cells to produce rodent insulin producing cells in 
vitro.  Clusters of these cells were then transplanted into the pancreas of live diabetic 
mice.  It was shown that within one week all symptoms of hyperglycemia had subsided 
and the mice were now able to naturally normalize their blood glucose levels after eating 
a meal (Soria et al., 2000).    
 Other successful ES cell studies have been conducted on animal subjects, mainly 
rodents.  ES cells have been used in the treatment of rats with severe spinal cord damage, 
as well as in the treatment of mice who suffer from hemophilia or cardiac problems.  In 
the spinal cord study, ES cells harvested from a mouse were transplanted into the 
damaged spinal cord of a rat after it suffered severe spinal trauma.  The rats were 
examined two to five weeks after ES cell injection, and it was shown that the transplanted 
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cells had survived and differentiated into cells that had begun to repair the damage from 
the initial trauma.  As a result of the production of new cells found in their nervous 
system, the rats showed improvement in their condition, as there was a noticeable 
improvement in coordination, and the rats were able to bear more weight on their hind 
limbs (McDonald et al., 1999).  In another study conducted at the University of North 
Carolina, hemophilic murine livers were injected with a compound made up of murine 
ES cells and natural growth factors.  The injected mice were then able to manufacture 
hepatocytes, which are the liver cells that produce the factor IX protein that leads to 
blood clotting.  The study also showed positive long term results, as the injected mice 
were continuing to naturally produce factor IX more than one hundred days after the 
initial injection procedure, showing that the mice experienced a complete remission of 
the hemophilia (Sciencedaily.com, 2005).   
 While embryonic stem cell research is undoubtedly the cutting edge of newly 
developing medical treatments, the ES cell studies conducted so far have been done 
exclusively on animals because there have not been any studies approved for human 
testing.  However, since the animal studies have shown a lot of positive results, it is likely 
only a matter of time until researchers receive approval to begin the ES cell research in 
human test subjects.     
 
Chapter Conclusion 
Stem cell research, clinical trials, and successful applications that have been 
conducted or are being currently conducted are most likely only beginning to scratch the 
surface of what science will be able to use these “master cells” for as human technology 
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and understanding of the body increases in the future (Earll, 2005).  A White House 
report from 2001 discusses how even five years ago when many of these studies were in 
their early stages it was still believed that stem cell research could lead to the 
development of therapies that could be used to combat diseases that more than one 
hundred and twenty million American citizens suffer from (Viacord, 2002).  Future 
advancements could include, but are certainly not only limited to, the use of stem cells in 
the tissue engineering and production of new organs, skin, cartilage, ligaments, and 
tendons for transplant, as well as the ability to help reverse the effects of diseases that 
arise as people age such as Alzheimer’s disease, osteoporosis, and perhaps even being 
able to be used against the aging process itself (Stem Cells:  Scientific Progress, 2001).      
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CHAPTER-3: STEM CELL ETHICS  
 
The moral dilemmas presented by stem cell research are as diverse as the 
research.  These concerns take the form of both moral and religious objections.  This is 
not to say that all religious groups see the issue in the same light.  There is dissent even 
among the Christian community as to the morality of the issues.  This section will first 
explore the main moral issues with stem cell research.  The second section will provide 
insight to the views of various religions on the contested issues of ES and EG research.  
This section will present little detail on adult stem cell research as there is little objection 
to this research among the religious communities. 
 
Adult Stem Cell Ethics 
The average person needs to consider adult stem cell research before they decide 
to be against all stem cell research.   Much of the adult stem cell research is already 
accepted in mainstream society.  Few people would pause to consider the morality of 
receiving a bone marrow transplant if they were suffering from leukemia or lymphoma, 
even though they might not be aware this is a direct application of stem cell research.  
The hematopoietic stem cells, located in the marrow, are the cells which restore the 
hematopoietic system of the patient. Without any stem cell research, bone marrow 
transplants would not exist and thousands of people’s lives would not have been saved.  
Continuing research with adult stem cells has resulted in other potential treatments, 
including the ability to repair damaged heart muscle, repair damaged nerves in the spinal 
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cord, and to create antibodies that attack tumors.  Current research has pushed the bounds 
of what adult stem cells are capable of.  There are few, if any, moral objections to 
research to find the capabilities of adult stem cells since no embryos are destroyed to 
obtain them.  With research showing that stem cells, once thought to produce only cells 
from their native system, are capable of producing cells of a different tissue, the uses of 
adult stem cells are increasing rapidly.  Unlike ES or EG cells, adult stem cells are 
collected without any lasting harm to the donor.  The ability to collect these cells without 
destroying a life (or even a potential life) allows the research to be conducted in good 
conscious.   
Some religious groups have pushed for increased adult stem cell research, and the 
cancellation of ES and EG research due to these factors.  They also feel that the stability 
of the adult cells makes them have a greater advantage over ES and EG cells.  ES and EG 
cells have been shown to differentiate quickly, after transplant, and have formed tumors.  
For these reasons, adult stem cell research should be fully supported both by public and 
private funding.  One of the few objections to adult stem cell research deals not with 
allowing adult stem cell research, but rather with the particular applications.  For 
example, some object to using mouse feeder cells to grow human ES cells, as they feel 
that cross species mixing might occur, and that would be morally hazardous.   
 
EG Cell Ethics 
EG research is a deeply emotional issue for many people.  Because aborted 
fetuses are used to obtain EG cells, people have very passionate feelings about it.  Some 
people see the great potential of the cells and see these stem cells as their only hope.  
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Others feel that the abortion of the fetus makes the research impossible to justify.  There 
are also those whose opinions fall in between the two extremes.  They feel it is acceptable 
to use fetal tissue, which would be normally thrown away, but would be firmly against a 
medical abortion that would be solely performed to obtain the tissue.  To the authors of 
this IQP, this stance is the most reasonable and should be encouraged.  To discard useful 
stem cells that might be used for the good of mankind just because they are obtained from 
an already aborted fetus is unreasonable.  This is not to say that abortion should be 
encouraged to provide a ready source of EG cells, but rather to say that abortion happens, 
and it is more wrong to discard the tissue than it is to put it to good use.   
Some are against EG research because they feel that the use of aborted tissue 
might encourage women to have abortions.  If the woman was unsure whether to keep the 
baby or to have an abortion, the usefulness of the tissue might push the woman towards 
abortion.  But to disallow all EG research because of this potential is foolhardy.  
Assuming one feels abortion is wrong, a person who decides to abort based on this flimsy 
excuse, would not be a person of moral standing.  They could be also expected to make 
immoral choices in other aspects of their life.  If society bans all EG research just to 
discourage the immoral individual, it would be ridiculous.  Society might was well ban 
medicine as it might be abused by immoral people.  All society can do is conduct morally 
upright research and hope that individuals will act in a moral and acceptable manner.  If 
one does not feel abortion is morally hazardous, then they would probably not object to 
EG research and thus need no convincing.  EG research has shown great potential and has 
resulted in the regeneration and repair of spinal cord nerves in mice.  Such advances 
could provide a great service to the human race, so continued research is quite merited. 
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ES Cell Ethics 
 ES research is one of the most controversial areas of scientific research today.  
The expectations are only matched by the dissent to the research.  The main moral 
dilemma is the destruction of the embryo, thus each person needs to make their own 
informed decision as to when life truly begins.  If the person determines that life begins at 
conception, ES research is harder, if not impossible, to justify.  If they feel that life begins 
later on, then they need to look at further issues before formulating an opinion on ES 
research such as whether the good of the potential treatments outweighs the destruction 
of the blastocyst.  They need to form a moral status for the potential life, and decide if the 
research is justified.  The thinking needs to then continue and consider the potential of 
adult stem cells, and see if they still feel ES research is justified, relative to the advances 
in adult stem cell research.  They need to consider the instability of the ES cells as 
compared to more mature stem cells.  The potential of ES cells to form tumors is quite 
alarming and should be carefully considered and neutralized if one wants to perform 
morally upstanding research on test subjects.  The embryos that are destroyed to create 
ES lines are typically those obtained from in vitro fertilization (IVF) clinics that are in 
excess of what the couple needed, and going to be discarded and die.  Since these are 
already doomed embryos, destroying them for research is just a different version of the 
same fate.  The researcher is not destroying a potential life that would have otherwise 
been allowed to live a full life.  This lessens the moral hazards of blastocyst destruction.  
A relatively new trend is the adoption of the extra embryos from IVF.  Surrogate mothers 
are used to implant the embryo, and the children are raised as their own.  This does not 
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imply that all of the stored embryos are saved, as a very small percentage is actually 
adopted. The adopted embryo children are often referred to as ‘snowflake’ children, in 
reference to the frozen embryos.    While all these concerns are quite justified, it is still 
possible to conduct the research in good conscious. 
 
Parthenote Ethics 
Parthenotes only further cloud the morality of ES research.  Because these 
artificial embryos are impotent to form a human, they have a lower moral status to most 
people.  Because they cannot be implanted and grown to term, destroying a parthenote is 
not destroying a potential life.  To decide the morality of ES research with parthenotes, 
one must decide where the line is between human life and cells containing the 
architecture for human life.  If these embryos (the size of the period at the end of this 
sentence) are just a collection of cells, and not a human, then harvesting the inner cell 
mass is ethical.   Parthenotes also have ethical issues due to the collection of the eggs.  
The eggs need to be harvested, using the same process as IVF.  The donor takes drugs 
that regulate hormonal levels.  The egg harvesting procedure increases the risk of certain 
cancers, such as ovarian and uterine cancer.  With each donation cycle, the risks increase.  
Because of the rising health risks resulting from the egg donation, safeguards need to be 
placed to limit the number of times a woman can donate her eggs for research. 
 
Inter-Species Ethics 
 There is also dissent to research that transplants tissue from one type of animal to 
another.  This is not as clear of an issue as it might appear on the surface.  By having the 
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ability to use stem cells from one animal to treat diseases or medical problems in another 
type of animal, researchers hope to one day possibly use animal stem cells to treat 
diseases in humans.  By using animal ES or EG cells to treat human diseases, the 
researchers could have the boundless potential of pluripotent stem cells, without having 
to destroy a human life or potential life.  One key issue here involves the potential 
transfer of animal viruses to human recipients, which is also a key ethical issue associated 
with xenotransplantation (the transplant of animal organs such as livers to humans). 
 
Catholic Stance on Stem Cells 
 The religions of the world have quite varied opinions when it comes to ES and 
EG research.  The Catholic Church’s strict rules concerning reproduction, and its views 
on the start of life make it one of the strictest against EG and ES research.  More liberal 
views come into play from Judaism and Islam, which might come as a surprise to many.  
Eastern religions, such as Hinduism and Buddhism, have objections that are not found in 
most western religions. 
The Catholic Church feels that adult stem cell research can be conducted 
ethically.  The Church’s position is that the research can be conducted for the good of 
mankind, without taking human life.  They also feel that human and animal tissues should 
be kept separate, as doing otherwise is too close to playing God.  Some Catholic bishops 
are pushing for adult stem cell research as part of their crusade against ES and EG 
research. 
The official Catholic perspective on ES research is one of the most rigid and 
strict.  The Catholic Church teaches that life begins at the moment of conception- as the 
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sperm and egg fuse.  This exact and early infusion of spirit and soul leads to a very 
staunch stance on ES research.    The Catholic Church believes that human life is sacred, 
and ending a life even to save many others, is morally and spiritually wrong.  Because 
Catholics believe that an embryo is a human life, destroying the embryo to harvest the ES 
cells is forbidden.  This even applies to the destruction of the blastocyst, when harvesting 
the inner cell mass.  The church believes that the greater good argument is not valid, and 
that only God has the power to decide when and which lives should end.  The Catholic 
perspective is that the harvesting of embryonic cells is not just morally equivalent to 
murder, but is actually murder, due to the destruction of the blastocyst.  This stance is not 
very surprising, as the Church is also firmly entrenched against abortion.  The Catholic 
Church’s stance against abortion leads them to also be against research with EG cells.  
The Church feels that aborted fetal tissue should not be used.  They are even opposed to 
the use of tissue from abortions that happen without regard to research.  They feel that the 
option of having the fetus donated for research may encourage women on the fence to 
decide to have an abortion.  The Catholic Church is also against the creation and use of 
parthenotes, partially due to the closeness to IVF.  The Church has strict rules regarding 
reproduction.  They believe that reproduction is a gift from God and that it should only 
occur between a man and a woman, within the bonds of marriage.  They feel that IVF 
occurs outside of marriage, and by removing intercourse from the equation violates 
God’s will.  This stance places the Catholic Church firmly against the use of the extra 
embryos created from IVF.  The Catholic Church feels that parthenotes also violate 
God’s will and are also too close to playing God, by creating ‘life’ outside of the way 
God intended.  
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Islam and Stem Cells 
The Islamic faith does not have an official position concerning stem cell research.  
There is no one central authority from which the position could emanate, which makes 
determining the moral position more difficult.  Iran, run by conservative Muslims, has 
officially allowed and supported ES research.  If this can be considered an indication of 
religious backing of ES research, the research may find a promising new home in Muslim 
countries around the word.  Iran is not the only Muslim country to openly support such 
research, Egypt and other countries also provide official support.   Many Islamic scholars 
believe that life does not start until around the fortieth day.  This position lines up with 
the Jewish perspective.  Other scholars contend that life does not begin that early, they 
believe it begins around the one hundred twentieth day.  This view is held by many Sunni 
and Shi’a Muslims, which believe ensoulment occurs around the 4th month, when the 
baby has its first movements.  These positions allow for little opposition to ES research, 
since life does not begin until the 40th or 120th day, destroying a blastocyst at day-5 does 
not constitute murder and is much more morally acceptable.  Many Muslims also feel 
that, because the embryo cannot survive on its own outside of the womb, it has a lower 
moral status.  Islamic scholars have described the process of becoming a person as 
gradual.  This leads to an even lower moral status for the blastocyst.   
However, there is some dissent among the Muslim community.  This is mostly 
limited to arguments that this research is a slippery slope that could lead to morally 
questionable practices.  They believe it could lead to the growth of humans for spare 
parts, the killing of babies for research, or other morally troubling situations.  Muslims 
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feel that EG research is acceptable, as the aborted fetus is not yet a human, and therefore 
is not afforded the same moral protection as an adult would have.  The EG cells are 
harvested from fetuses that are aborted in the 7th to 13th week, which is allowable in 
Islamic morality.  Islamic law allows for abortions up until the 4th month, which is well 
past the 7th to 13th weeks required to obtain EG cells.  
 
Church of the Latter Day Saints and Stem Cells 
 The Church of Latter Day Saints (LDS) has no official position on stem cell 
research.  The Church has issued statements describing stem cell research as meriting 
cautious scrutiny.  The LDS Church has a much more flexible position on the issues 
surrounding stem cell research than the Catholic Church does.  The LDS Church typically 
has been quick to embrace and support new technology.  The LDS Church believes that, 
prior to existence on earth, humans exist as a spirit child of God.  The spirit and flesh are 
joined, and then life begins on earth (Clark, 2001)  Senator Smith, a prominent Mormon 
politician, has gone on the record with a view of life beginning as a two step process.  He 
believes that the flesh comes first and then the union of flesh and spirit.   This separation 
of the creation of the flesh and the entrance of the spirit allow like minded Mormons to 
support embryonic stem cell research, because the embryo would be considered mere 
flesh, like an arm or leg, rather than a human life (Clark, 2001).  To many in the LDS 
Church, implantation is the key.  While being opposed to abortion, which is ‘too much 
like killing’ (Clark, 2001), embryonic research is acceptable since it is conducted prior to 
implantation.  The unofficial position of the LDS Church is that there is a need for stem 
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cell research. The research must be undertaken in a very cautious manner, and much 
thought should be directed at maintaining the highest moral standards. 
 
Buddhism and Stem Cells 
Buddhists traditionally believe that life begins at conception.  They believe that 
conception requires three things.  The first condition is a woman’s fertile period.  The 
second condition is it requires sex.  The last requirement for conception is a ‘being to be 
born’, that is ready for life.  Because of these beliefs, Buddhists are often against in vitro 
fertilization.  However, this leaves a bit of wiggle room for the liberal Buddhist.  If an 
embryo or parthenote is created outside of these conditions, such as in IVF, the traditional 
ethical rules do not directly apply to the embryo or parthenote.  This could allow for a 
Buddhist to argue that ES research could be conducted in good conscious, provided the 
ES cells were the result of IVF or from parthenotes.  Because one of Buddhism’s main 
tenants is to avoid doing harm to other living things, they are firmly entrenched against 
abortion.  Due to their moral objection to abortion, Buddhists are against the use of 
aborted tissue for EG research. 
As do many religions that believe in reincarnation, Buddhists have moral issue 
with the leftover embryos from IVF.  With ensoulment at conception, the soul remains in 
the body until death.  With a leftover embryo, the soul would remain trapped inside the 
embryo, until it was disposed of, wherein it would return in another life.  This is a 
disruption of natural order, as a soul could be reincarnated many times and never truly 
live.  It would also be possible for the soul to be trapped, indefinitely, in a leftover 
embryo that was frozen.  For these reasons, religions that believe in reincarnation tend to 
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have issue with the process of IVF and find it very morally troubling.  This leads to a 
belief that they cannot, in good conscious, support ES research that uses embryos from 
IVF or parthenotes.   
 
Hinduism and Stem Cells 
Hindus do not have an all encompassing belief that dictates ethics for ES research.  
Hindus believe that life begins at conception.  They do not believe that an embryo or 
fetus is growing into a human, but rather that the embryo is a full fledged human being.  
Their religion teaches that abortion is killing, and that it is among the worst of crimes.  
This belief is contradicted by the cultural preference for male children and the practice of 
selected abortion of female embryos.  This practice is carried out because some feel that 
the burden of having a female child is greater than the wrongful killing a child.  This is 
not meant to imply that it is considered acceptable, moral behavior, but rather to show 
that there is some leeway in the community.  Hindus believe that in certain, absolutely 
necessary situations, it is acceptable to kill an embryo, provided that it is for the greater 
good (Reichhardt- 2004).  In this sense, ES research does not qualify as ethical behavior, 
because the research itself is not strictly necessary, even though it is for the greater good.  
This view is also due to the ability of adult stem cells to form such diverse types of cells, 
rendering the destruction of embryos avoidable in most circumstances. 
 
Chapter Conclusion 
Each person needs to evaluate their own position on stem cell research.  They 
need to take into consideration their religious, personal, and societal views, and formulate 
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their own standards by which they can determine what type of research is merited.  
Though there may never be a consensus on when life truly begins, the scientific 
community can still produce amazing, new advances in stem cell research.  They can 
achieve this while taking religious and moral implications of the research into 
consideration. 
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CHAPTER-4:  STEM CELL LEGALITIES 
 
Because stem cells are ethically controversial, laws are in place regulating their 
use.  The legalities dealing with stem cell research and applications vary from country to 
country.  The national stem cell research policies found worldwide arise from a mixture 
of factors including the country’s political and social climate, level of scientific and 
industrial development, and strength of economy.  From a global perspective, every 
country has unique policies regarding stem cell research and clinical usage, but overall 
there are three main types of stem cell legislation categories which countries can be 
grouped in.  In the first group there are more than ten countries, primarily located in 
Europe and Asia, which have passed liberal federal legislations allowing scientists in 
their boarders to openly conduct research into all areas of stem cell technologies, 
including somatic cell nuclear transfer (SCNT).  SCNT is defined as the implantation of a 
nucleus from a somatic or body cell into an egg that has had its original nucleus already 
removed (Hoffman, 2005).  Most of the nations that have approved this kind of open 
stem cell research are larger, more developed countries such as the United Kingdom, 
China, India, Japan, Sweden, and Israel.   
The second group includes many more countries that have taken a milder stance 
on approving stem cell research, that mainly allows scientists to use stem cells that are 
harvested from embryos obtained from fertility clinic donations, as long as the harvesting 
is within federal guidelines.  The embryos that are available for stem cell research are 
embryos that are leftover from in vitro fertility procedures that are no longer needed.   
Countries that fall into this category include Canada, France, Australia, Spain, and Brazil. 
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Again, each country in this group has individual policies, but all countries in this group 
meet the general standard of currently allowing the harvest of embryonic stem cells to 
some degree.   
The final stem cell policy group has members such as the United States, 
Germany, Italy, Ireland, and Norway.  Countries in this group either do not allow the 
harvesting or use of embryonic stem cells at all, do not have established policies dealing 
with stem cells, or strictly limit and monitor the use of human embryos and stem cell 
harvesting.  Ireland and Norway are countries in this category that are on the stricter end 
of the spectrum, while the United States, Germany, and Italy are the more liberal 
countries in this group that closely monitor and regulate the use of human embryos in 
scientific research (Hoffman, 2005).    
 
United States Stem Cell Legalities 
 
Federal Stem Cell Research Policy 
  In the United States, stem cell research is governmentally regulated, and 
compared to many other nations the US falls into the most restrictive of the three 
categories as it holds fairly strict policies limiting what type of scientific research can be 
conducted with federal funds.  However, aside from Federal guidelines, some individual 
states have established their own stem cell research policies by enacting statewide 
legislation.   
 As a whole, American stem cell research is regulated by the Office of Human 
Research Protections (OHRP), which is a division of the federal Department of Human 
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and Health Services (HHS).    All American researchers wishing to conduct any sort of 
human or animal testing studies, whether it is federally or privately funded research, must 
abide by an assortment of government guidelines.  These regulations require the 
institution at which the study will be conducted to be pre-approved for OHRP assurance 
that all testing will apply HHS guidelines and its human subjects protection regulations, 
and that all tests and devices used in the study must meet the standards set by the Federal 
Drug Administration that govern the use of investigational new drugs (INDs) and 
investigational devices (IDEs).  Furthermore, clinical stem cell studies pertaining to the 
transplant of human fetal tissue into human subjects must abide by Public Law 103-43, 
which is titled, “Research on Transplantation of Fetal Tissue”.  There also may be state or 
local laws that can further regulate research conducted using human stem cells 
(Regulations and Ethical Guidelines, 2005).     
 The policies outlined by the OHRP for federally funded human embryonic stem 
cell research follow federal legislative regulation and the general criteria established by 
President George W. Bush in August of 2001.  The OHRP regulations for federally 
funded stem cell research approve studies into the derivation and use of human 
embryonic stem cells as long as the stem cell lines used in the clinical trials were 
obtained prior to 9:00 PM (Eastern Standard Time) on August 9th, 2001, and that the stem 
cells were harvested from embryos that were created for reproductive purposes and are 
no longer needed (NIH’s Role in Federal Policy – Stem Cell Research (2005).  Other 
possible sources for embryonic stem cells are embryos produced by cloning, and embryos 
from aborted pregnancies, both of which are not approved ES cell sources in the United 
States.    
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According to President Bush’s statement, by August of 2001, scientists from ten 
laboratories across the world were able to isolate, harvest, and store ES cells from 
seventy one genetically unique blastocysts.  Blastocysts form between four and seven 
days after the embryo originates, and are hollow spheres surrounded by cells that result 
from the development of totipotent cells (Pelletier et al., 1999).  To summarize the 
criteria outlined by President Bush, the United States government will approve federal 
funding for human embryonic stem cell research that uses stem cell cells from the 
seventy one different cell lines harvested before August 9th, 2001; any research that 
results in the harvesting of new human embryonic stem cells from any source will not 
receive federal funding collected from taxpayers (Pizzi, 2002).  However, there is no 
federal legislation that absolutely forbids scientists from developing new stem cell lines 
with private funds, but the costs associated with ES cell harvesting are so high that no 
researchers have been able to successfully raise enough money to conduct privately 
funded research (Holden, 2002), although recent state bonds may alter this.  In 2002, 
Stanford University announced plans to try and privately raise enough capital to become 
the only institution in the United States to privately fund their own stem cell research, 
possibly even forming their own ES cell lines (Check, 2002).   
 Despite the federal legislation restricting stem cell research that has been passed, 
and lack of federal funding limiting ES cell research, the majority of the United States 
public supports additional stem cell research.  Fifty-eight percent of Americans are in 
favor of the conduction of further stem cell research; with sixty percent of those 
questioned believing that the federal government should fund these projects (Langer, 
2005).   However the percentages determined in this poll are somewhat misleading as to 
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the beliefs of the voting public.  National voter turnout rates range between just fifty five 
and sixty percent for most elections, including presidential elections.  In the past couple 
of elections there has been strong conservative backing among the majority of the voting 
public, leading to the election of a republican into the presidential office and a republican 
majority in the senate (McDonald, 2006).  Because republicans as a group are mainly 
pro-life and against ES cell research, and the majority of the voting public does not share 
the same views as the people questioned in the McDonald poll, it is unlikely that there 
will be any federal reforms to U.S. current stem cell legislation in the near future.    
 
State Stem Cell Research Policies 
The United States is different from other countries in regards to its policies on 
stem cell research because scientists must deal with federal guidelines that regulate 
government approval of stem cell research, as well as locally enacted state legislature.  
All states allow research into stem cell types such as HSCs, neural stem cells, 
mesenchymal stem cells, endothelial stem cells, etc. as long as the work meets the 
guidelines set by the FDA.  In some states these local policies allow for scientists to have 
more freedom in their work, primarily dealing with ES cells.  States such as California, 
Illinois, Ohio, and New Jersey have all passed statewide legislation allowing for more 
work to be conducted using ES cells, with Illinois going as far as to have issued an 
executive order that encourages further work with ES cells.  All of these states allowing 
ES cell research have established a system of regulations and monitoring to ensure that 
the research being conducted meets the legal and ethical standards that have been 
established.  However, almost half of the states in the U.S. have enacted state laws 
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restricting research on embryos in one way or another, ranging from the restriction of the 
sale of embryos in many states, to the prohibition of all research on embryos in South 
Dakota.   
In 2004, Ohio became the first state to allocate state funding for research projects 
dealing with adult stem cells, and the state legislature is beginning to take further steps to 
set aside more state funds specifically for ES cell research (Ertelt, 2005).  Shortly after 
Ohio began to support stem cell research in early 2004, the state of New Jersey enacted 
the first legislature that allocated taxpayer’s money for ES cell research.  New Jersey has 
given more than twenty million dollars to the New Jersey Stem cell Institute, and a state 
ballot initiative that would allow for the increase of its stem cell institute’s funding to one 
hundred and fifty million dollars, as well as the allocation of two hundred and thirty 
million more dollars in research grants.   
California became the next state to fund embryonic and adult stem research in 
2004 with the passing of Proposition 71.  Proposition 71 set aside three billion dollars in 
bonds that can be distributed yearly in amounts not to exceed three hundred and fifty 
million dollars, to stem cell research, including those projects dealing with ES cells 
(National Conference of State Legislatures, 2006).   
In 2005, Connecticut also passed a bill through their State Assembly which 
allowed for state money to be used to fund both ES cell and adult stem cell research.  The 
Connecticut stem cell bill allows for the distribution of one hundred million dollars of 
state money to Connecticut based stem cell laboratories over a ten year period 
(Associated Press, 2005).  Rod Blagojevich, governor of Illinois, issued his executive 
order in April of 2006.  The executive order that Blagojevich signed not only 
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appropriated ten million dollars in state funds for embryonic and adult stem cell research, 
but also resulted in the formation of the Illinois Regenerative Medicine Institute.  Also in 
2006, Maryland formed the Maryland Stem Cell Research Fund, and beginning in 2007, 
fifteen million dollars will be included in the state budget to be used for ES and adult 
stem cell research.   
Other states like Massachusetts are taking steps towards the proposition of a bill 
before their state legislatures which would also support the funding of stem cell research.  
In 2005, the Massachusetts state legislature was able to override a veto by the governor 
and enact Senate Bill 2039.  Bill 2039 resulted in the formation of a council to examine 
the use of public funds for the formation of a regenerative medicine institute within the 
University of Massachusetts Medical School (Worcester), and research on stem cells that 
have been harvested specifically from umbilical cord blood (National Conference of State 
Legislatures, 2006).   
 
Stem Cell Legalities in Countries Outside of the United States 
 
 Unlike North American nations which mainly have strict stem cell policies, there 
are many countries in the world that fit into all of the three categories that describe the 
strictness of their national stem cell research policies.  The United Kingdom, South 
Korea, and Sweden fall into category I.  Category I consists of the countries that are the 
most permissive to all types of stem cell research and have very liberal national policies 
that regulate stem cell research.  France, Spain, Australia, and Canada are the larger 
countries grouped into category II, where stem cell research is supported by the 
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government, but is also closely monitored and regulated. Finally, Germany and the U.S. 
head up category III, consisting of countries which all have fairly strict stem cell 
legislation and regulations, mostly pertaining to ES cells, some of which are similar to 
those stem cell policies found in the United States. 
 
Category I Policies 
 The United Kingdom was one of the first countries in the world to pass legislation 
that dictated what experiments researchers could legally conduct with human embryos 
with the enacting of the Human Fertilisation and Embryology Act of 1990 (Garfinkle, 
2004).  The purpose of the 1990 Act was mainly to set legal guidelines for researchers 
studying the use of embryos in reproductive procedures.  In 2001, the previous Act was 
reexamined and expanded to include sections with regulations for ES cell and other types 
of embryonic research.   This new act included the development of a national cell bank 
that will be run by the country’s Medical Research Council, and will contain an 
assortment of embryonic stem cell lines that are available to English researchers.  The 
bank will receive these cell lines from laboratories which are granted yearlong licenses 
that permit the isolation and harvesting of individual cell lines.  These licenses are 
awarded by the United Kingdom’s Human Fertilisation and Embryology Authority.  
Once the license expires, scientists are restricted by a policy somewhat similar to that 
found in the United States where research can only be conducted using the cell lines 
harvested before the expiration of that license, unless a new license is granted.  Several 
licenses have been granted to English research facilities beginning in early 2002 with 
London’s King’s College (Garfinkle, 2004).   
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Sweden might have one of the most desirable political and scientific climates for 
stem cell research.   Stem cell research, including ES cell studies, has been widely 
supported by the public and the government for years, dating back to the 1980’s with 
early treatment methods of Parkinson’s disease, which has resulted in some of the most 
liberal stem cell legislation found in the world.  Overall, there are more than thirty 
research groups and ten institutions located in Sweden conducting widespread stem cell 
research.  Sweden established a national cell line bank shortly before the United 
Kingdom, which made it the first of its kind in the world.  Laws have been established 
that allow the harvesting of ES cells from embryos created during in vitro fertilization 
procedures, as well as the use of cloning for therapeutic purposes.  Both of these areas of 
research are highly debated in most countries due to ethical concerns, but have received 
very little opposition from Swedish citizens.  As a result of their country’s very open 
stem cell policies, Swedish researchers often receive monetary support from sources in 
other countries, including America.  Charities in other countries that support research into 
the treatment of diseases such as Parkinson’s disease and heart disease give money each 
year to Swedish researchers because they are allowed to conduct research which would 
not be permitted in the charity’s home country (Sweden’s Stem Cell Successes, 2002).    
In 2005 South Korea decided to expand on Sweden’s idea of a national stem cell 
bank, and announced the formation of a worldwide stem cell bank.  This cell bank would 
provide access to pre-made unique and diverse cell lines for scientists all over the world, 
including those located in countries like the U.S. that do not allow further harvesting of 
ES cells.  The cell bank will be part of the “World Stem Cell Foundation” and was 
headed by Woo Suk Hwang (prior to his recent resignation), who was the first scientist to 
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ever clone a human embryo for the purpose of harvesting its ES cells.   The World Stem 
Cell Foundation is located at South Korea’s Seoul National University, and will 
hopefully be able to produce more than one hundred stem cell lines per year.  Using the 
SCNT technique, scientists can also produce stem cells that are based on specific DNA 
provided by the buyers, so that the resulting cells will have the genetic characteristics 
necessary for their study.  The development of this worldwide cell bank is important 
because it will provide an avenue for scientists to obtain ES cells without obtaining 
government funding to pay for the harvesting process, essentially circumventing many 
country’s legislation that is aimed at preventing this type of research on ES cells (Kaplan, 
2005).     
 
Category II Policies 
 Australia is a major player in global stem cell research, with Australian research 
teams conducting studies using stem cells to test the effects of drugs on human cells 
using in vitro studies, as well as experiments studying the effects of stem cell therapies on 
diseases such as heart disease and leukemia.  Australia is considered a middle of the road 
country in terms of how strict its policies are dealing with stem cell research, resulting in 
it being grouped into category II.  National policies found in countries from category II 
slightly resemble those found in both the category above and below it.  Federal policy 
was established by lawmakers by the enacting of two acts in 2002, the Prohibition of 
Human Cloning Act, and the Research Involving Human Embryos Act.  The first act bans 
all human cloning, regardless of purpose, while the second act sets precedent allowing 
state approved laboratories to harvest ES cells from embryos obtained from fertilization 
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clinics. Australian researchers that meet the strict conditions for research approval stated 
in the Research Involving Human Embryos Act may apply for a government license to 
harvest ES cells that is awarded by the National Health and Medical Resources Council.  
Like the UK and South Korea, Australia also established a national group which received 
the bulk of national funding for stem cell research in 2003 called the Australian Stem 
Cell Center (Stem Cell Research in Australia, 2003). 
 The other larger countries grouped into category II have all passed similar 
legislation.  These countries are not as open to the outright funding of ES cell research, 
they all have some sort of stringent guidelines in place to ensure that only approved 
research is being conducted.  Essentially all of these countries with moderate policies do 
allow further harvesting and research of ES cell lines, like legislation found in category I 
countries, but all have stricter laws to regulate these studies, similar to those policies 
found in category III countries.   
 
Category III Policies 
 Category III countries all have stem cell policies similar to those found in the 
United States and Germany.  Germany is a country that has been at the front of 
technological and scientific advances for hundreds of years, but with very strict stem cell 
research regulations, is likely to struggle to keep up with countries like South Korea and 
the UK in the future of stem cell technology.  Germany has had federal legislation in 
place for more than a decade that outright bans research on human embryos.  This means 
that German scientists were never able to harvest any ES cells, and as a result they do not 
have any cell lines in storage that were established by their scientists.  However, German 
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researchers have been able to import cell lines from other countries, as these cell lines 
and their import had not been explicitly prohibited by German law.  Unfortunately for 
German scientists, in 2002 the German parliament passed legislation that severely limited 
their ability to import cell lines.  The new legislation does allow the import of ES cells 
under strict regulations and monitoring by the German government.  Many of Germany’s 
citizens and politicians favor an outright ban of ES cell importation, with the new 
legislation narrowly being approved by Parliament, and receiving a lot of criticism from 
German Catholics and Protestants who support an outright ban of ES cell research (Kim, 
2002).    
 It is likely that as long as countries like the United States and Germany continue 
to impose strict legislation regulating ES cell research, many other countries will also 
uphold similar stem cell legislation, as these two world powers are often looked to set 
precedent for legislation found in other countries.   
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CONCLUSIONS 
 
 Stem cells are long-lived cells in the body that have the ability to differentiate into 
a specialized cell to create new tissues.  Because of this tissue regenerative capacity, stem 
cells are currently at the forefront of medical research and development.  It is believed 
that as stem cell research and therapies continue to advance, doctors will be able to offer 
more effective treatment methods for many of the diseases that affect humans.  Based on 
a substantial amount of animal research with both adult and ES stem cells, doctors around 
the world have already conducted human research studies that have yielded positive 
results, however it is likely that these early clinical trials and applications have just begun 
to scratch the surface of what science will be able to use these “master cells” for in the 
future.   
 However, as with all change and technological advancement, stem cells have 
presented new moral dilemmas that are as diverse as the research being conducted.  
Ethical concerns relating to moral and religious objections to stem cell research are being 
debated among politicians, theologians, and average citizens on a daily basis.  Most of 
the world’s main religions support adult stem cell research, however only the Muslim and 
Jewish faiths support ES cell research.   
 As a result of these beliefs, most countries have chosen to take a national stance 
on stem cell research, enacting some sort of federal legislation to set regulations for their 
researchers to follow.  Due to unique political and ethical climates, national stem cell 
policies typically vary from country to country; and in cases like the United States, state 
policies can help compensate for a stifling federal ES policy. 
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